Wade T. Iams, MD, discusses the emergence of TKIs and antibody-drug conjugates in HER2-mutant lung cancer.
Wade T. Iams, MD, assistant professor of medicine, Vanderbilt University Medical Center, discusses the emergence of TKIs and antibody-drug conjugates (ADCs) in HER2-mutant lung cancer.
In the setting of HER2-mutant non–small cell lung cancer (NSCLC), TKIs, such as mobocertinib and poziotinib, and ADCs, such as fam-trastuzumab deruxtecan-nxki (Enhertu), are emerging as potential treatment options for patients, says Iams.
Although mobocertinib and poziotinib have demonstrated efficacy in this patient population, the field appears to be moving toward implementing ADCs before TKIs, Iams explains. In May 2020, the FDA granted a breakthrough therapy designation to trastuzumab deruxtecan for the treatment of patients with previously treated, HER2-mutant, metastatic NSCLC. Most recently, on March 11, 2021, the FDA granted a fast track designation to poziotinib for the treatment of patients with previously treated, HER2 exon 20–mutant NSCLC.